Skip to main content
2024 Guide to Patient Support Services

Boehringer Ingelheim

2024 PSS Guide

Boehringer Ingelheim Support Services

Boehringer Ingelheim offers the Gilotrif Patient Services program to provide appropriate information and assistance to patients taking Gilotrif (Table).

Gilotrif Patient Services

This program offers a Co-pay Assistance Program, Bridge Program, and Gilotrif Dose Exchange program. The BI Cares Patient Assistance Program is offered through the Boehringer Ingelheim Cares Foundation.

Co-pay Assistance Program

Patients may be eligible for the Co-pay Assistance Program if they are 18 years of age or older and have commercial insurance. To enroll your patient, visit the Co-pay Assistance Program.

Bridge Program

Eligible patients experiencing more than a 5-day payer approval delay can receive a 15-day supply of Gilotrif at no cost to the patient for the FDA-approved indications.

To enroll your patient, visit the Bridge Program.

Gilotrif Dose Exchange

This program covers up to 2 dose modifications for patients serviced through Accredo Specialty Pharmacy or Gilotrif Dispensing Network who have 9 or more tablets to exchange.

To learn more about the Gilotrif Dose Exchange program, call 844-569-2836.

BI Cares Patient Assistance Program

This program is offered through the Boehringer Ingelheim Cares Foundation and provides Boehringer Ingelheim medicines free of charge to uninsured and underinsured patients.

To learn more call 800-556-8317 or visit the BI Cares Patient Assistance Program

TABLE Boehringer Ingelheim Oncology Drug

Patient support programs

Gilotrif (afatinib)
First-line treatment of metastatic non–small cell lung cancer (NSCLC) with nonresistant EGFR mutations, as detected by an FDA-approved test; treatment of metastatic squamous NSCLC progressing after platinum-based chemotherapy
Patient support programs

EGFR indicates epidermal growth factor receptor; NSCLC, non–small-cell lung cancer.